News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Concert Pharmaceuticals, Inc. (CNCE) Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis 4/29/2016
ImmunoGen (IMGN) Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 4/29/2016
Corcept Therapeutics Inc. (CORT) Release: Promising Pre-Clinical And Phase 1 Data Support Advance Of Selective Cortisol Modulator CORT125134 As Potential Treatment For Cushing's Syndrome And Solid-Tumor Cancers 4/29/2016
Cytuvax Reports Interim Results Of The Phase I Clinical Trial With The HBAI20 Hepatitis B Vaccine For Non-Responders 4/29/2016
DURECT (DRRX) Announces Closing Of Public Offering Of Common Stock 4/29/2016
Seattle Genetics (SGEN) Reports First Quarter 2016 Financial Results 4/29/2016
IBC Generium Selects Goodwin Biotechnology, Inc. To Optimize The Process, Scale-Up, And Manufacture An Igg-Based Bispecific Antibody For Phase I Clinical Trials 4/28/2016
Regen BioPharma 's HemaXellerate Therapy For Treating Aplastic Anemia Licensed For Proof Of Concept Study 4/28/2016
RXi Pharma (RXII) Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model 4/28/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results 4/28/2016
Agenus (AGEN) Reports First Quarter 2016 Financial Results And Operational Progress 4/28/2016
Alkermes (ALKS) Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results 4/28/2016
Agenus (AGEN) Commences Phase I Clinical Trial Of Its CTLA-4 Checkpoint Antibody To Treat Solid Tumors 4/27/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
Exicure Announces Dosing Of First Patient In Phase I Trial For The Treatment Of Chronic Plaque Psoriasis 4/26/2016
ProtoKinetix Inc. (PKTX.OB) Outlines Steps To Clinical Trial Application For AAGP 4/26/2016
Asterias Biotherapeutics To Present At Stem Cell Summit 2016 4/26/2016
Queen’s University Belfast And Domainex Ltd Win Late-Stage Award To Progress Novel Lung Cancer Drug Candidate Into The Clinic 4/26/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR 4/25/2016
Fibrocell Science, Inc. Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma 4/25/2016
Allovate Announces Positive Results Of Proof-Of-Concept Study Of Oral Mucosal Immunotherapy (OMIT) 4/25/2016
Protalex, Inc. (PRTX) Announces Preliminary Findings From Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/25/2016
Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective 4/25/2016
Cerulean Pharma Inc. (CERU) Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference 4/25/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
NeuralStem Inc. Receives NASDAQ Notice Of Bid Price Deficiency 4/22/2016
Viveve Announces Positive Topline Results For VIVEVE I Clinical Trial 4/22/2016
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates 4/21/2016
DelMar Pharma Release: FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer 4/21/2016
ARMO BioSciences Announces AM0010 Clinical Data To Be Presented At The ASCO Annual Meeting In June 2016 4/21/2016
Inotek Pharmaceuticals Corporation (ITEK) Announces Publication Of Phase 1 Data For Trabodenoson In Healthy Adult Volunteers In The Journal OfOcular Pharmacology And Therapeutics 4/21/2016
Deciphera’s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition As A Single Agent And In Combination With An Anti-PD1 Inhibitor 4/20/2016
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor 4/20/2016
Xcovery Presents Data Supporting The Potential Efficacy Of X-396 In Patients With ALK+ Non-Small Cell Lung Cancer At The AACR Annual Meeting 2016 4/20/2016
N&N Pharmaceuticals Inc. Commences Clinical Trials On Its Novel Antiviral Drug 4/20/2016
CytRx (CYTR) To Present Updated Aldoxorubicin Clinical Trial Data At The ASCO Annual Meeting In June 2016 4/20/2016
Checkmate Appoints David Mauro, M.D., Ph.D., As Chief Medical Officer And Announces Dosing Of First Patient In Immuno-Oncology Phase 1b Trial With CMP-001, A TLR9 Agonist 4/20/2016
Merck & Co. (MRK) Statement On Blueprint Project Findings Presented At The AACR 2016 Annual Meeting 4/20/2016
iCardiac Technologies Implements New Quality Metric To Enhance Reliability Of Phase I QT Assessment 4/20/2016
vTv Therapeutics Presents Data On Two Diabetes Candidates At Keystone Symposia On New Therapeutics For Diabetes And Obesity 4/20/2016
AmpliPhi Bio (APHB) Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort 4/20/2016
Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies 4/19/2016
Celsion (CLSN) Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin And Doxil 4/19/2016
Lycera Announces Progress In Immuno-Oncology Program Presented At The 2016 AACR Annual Meeting 4/19/2016
BeiGene Presents Positive Interim Data From Trial Of RAF-Inhibitor 4/19/2016
DelMar Pharma Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At AACR Annual Meeting 4/19/2016
ContraVir Doses First Subject In Phase 1b Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection 4/19/2016
RXi Pharma (RXII) Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109 4/19/2016
Lpath (LPTN) Reports Favorable Results From Phase 1 Study Of Lpathomab 4/19/2016
BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016 4/19/2016
Sangamo (SGMO) Announces Presentations On ZFP Therapeutic Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy 4/19/2016
EBOVAC1 Release: Global Public-Private Partnership Announces Publication Of Positive Phase 1 Data For Ebola Vaccine Regimen In JAMA 4/19/2016
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation 4/19/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
Kite Pharma (KITE) Cancer Therapy Responses in Solid Tumors Continued in Small Trial, NCI Review Halts Patient Enrollment 4/18/2016
FDA Designates Merck & Co. (MRK)'s Keytruda a Breakthrough for Classical Hodgkin Lymphoma 4/18/2016
MabVax Therapeutics' Fully Human Antibody Approach To Cancer Therapeutics And Imaging Featured In Three Presentations At AACR Annual Meeting In New Orleans 4/18/2016
Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration 4/18/2016
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present REOLYSIN Preclinical Research At The 2016 AACR Annual Meeting 4/18/2016
Fibrocell Science, Inc. And Intrexon Announce Allowance To Commence Phase I/II Trial For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 4/18/2016
Cyclacel Pharmaceuticals, Inc. (CYCC)’s Second-Generation CDK2/9 Inhibitor, CYC065, Is An Effective Inducer Of Cell Death In B-Cell Lymphoma And Synergizes With Bcl-2 Or BET Inhibitors 4/18/2016
Incyte (INCY) Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio 4/18/2016
SAGE Therapeutics (SAGE) Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy of Neurology Annual Meeting 4/18/2016
ImmunoGen (IMGN) Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia 4/18/2016
Ignyta (RXDX) Announces Updated Data From Entrectinib Phase 1 Clinical Trials At The 2016 AACR Annual Meeting 4/18/2016
Endece To Present Data On NDC-1308, A Small Molecule With Remyelinating Activity For Treatment Of Secondary Progressive Multiple Sclerosis 4/18/2016
Merus To Present Interim Clinical Data From Ongoing Phase I/II Clinical Trial Of Its Lead Bispecific Antibody Candidate, MCLA-128, At The AACR 2016 Annual Meeting 4/18/2016
Loxo Oncology (LOXO) TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update 4/18/2016
Debiopharm Announces Presentation At AACR Of Non-Clinical Data Relating To Its Targeted Investigational Compound Debio 1347/CH5183284, A Selective FGFR 1,2,3 Inhibitor 4/15/2016
Sarah Cannon Research Institute To Present Cancer Research Insights At 2016 AACR Annual Meeting 4/15/2016
Marinus Pharmaceuticals (MRNS) Receives FDA Orphan Drug Designation For Ganaxolone IV To Treat Status Epilepticus 4/15/2016
MabVax Therapeutics Hires Paul Resnick, M.D. As Chief Business Officer 4/15/2016
Tunitas Therapeutics Expands Board Of Directors With Appointment Of Dr. Mervyn Turner 4/14/2016
Juno (JUNO) Announces Data Presentations At The AACR Annual Meeting 4/14/2016
DS Biopharma Presents Late-Breaking News Abstract On DS102 At The European Association For The Study Of The Liver (EASL) International Liver Congress; "DS102: A Bioactive Lipid For The Treatment Of NASH" 4/14/2016
Booming Seres Therapeutics Looks to Move Lead Product into Phase III, Expand in Cambridge 4/14/2016
Noveome Debuts with Top-Line Data from Three Phase I Clinical Trials 4/13/2016
DURECT (DRRX) Announces FDA Acceptance Of REMOXY NDA, PDUFA Date Of September 25, 2016 4/13/2016
PDS Biotechnology Corporation Reports Positive Phase 1 Study Results For PDS0101 Immunotherapy For HPV-Related Cancers 4/13/2016
Oncternal Therapeutics Awarded Exclusive Worldwide License To ROR1 Antibody And Related Programs From University of California, San Diego (UCSD) 4/13/2016
Apexigen To Present Data On Its Novel Immuno-Oncology Program APX005M At Upcoming Cancer Conferences 4/13/2016
Proteon (PRTO) Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease 4/13/2016
AmpliPhi Biosciences Corporation (APHB) Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients 4/13/2016
Karos Pharmaceuticals Advances Development Of KAR5585 To Treat Pulmonary Arterial Hypertension Into The Clinic 4/13/2016
107th Annual Meeting Of AACR: Bayer (BAY) To Present New Data On Advancing Oncology Portfolio 4/13/2016
Arena (ARNA) Reports Favorable Results From Phase 1b Multiple-Ascending Dose Clinical Trial Of APD371 4/12/2016
Rigel (RIGL) Announces Presentations At Upcoming AACR Conference 4/12/2016
Celsion (CLSN) Announces Upcoming Presentation At AACR 2016 Highlighting Potential Of GEN-1 IL-12 Immunotherapy In Ovarian Cancer 4/12/2016
Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data At Annual AACR Meeting April 18th In New Orleans 4/12/2016
Cellecta, Inc. SBIR Grant Work Finds Way To Increase CRISPR Effectiveness For Genetic Screens 4/12/2016
Adocia Initiates A Phase 1/2 Clinical Trial On The Post-Meal Effect Of Rapid-Acting Human Insulin, HinsBet U100 4/12/2016
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689 4/12/2016
NMT Pharmaceuticals Singapore Announces Signing Of Licensing Agreement With CAO Pharmaceuticals USA On Anti-Cancer Drug CZ-48 And Initiation Of Phase I Study 4/11/2016
Viking Therapeutics (VKTX) Presents Positive Phase 1b Clinical Data On VK2809 In Hypercholesterolemic Subjects 4/11/2016
ORYZON Genomics Release: Data On ORY-1001 To Be Presented At The AACR Annual Meeting 2016 In New Orleans 4/11/2016
Ignyta (RXDX) Announces Oral Plenary Presentation And Poster Presentations At The 2016 AACR Annual Meeting 4/8/2016
Galapagos (GLPG.BR) And MorphoSys AG Initiate Phase I Study In Joint Antibody Program MOR106 4/7/2016
Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters 4/7/2016
CANBridge Life Sciences Submits Investigational New Drug Application To Taiwan Food And Drug Administration For CAN-008 Phase I/II Trial In Glioblastoma 4/7/2016
REMD Biotherapeutics Announces Dosing Of First Type 1 Diabetes Patient With REMD-477, A Glucagon Receptor Monoclonal Antibody 4/6/2016
Cidara Therapeutics (CDTX) Announces Presentation Of Data From Its Antifungal Drug Development Programs At ECCMID 2016 4/6/2016
Merck & Co. (MRK) To Present New Data For KEYTRUDA (pembrolizumab) At The AACR 2016 Annual Meeting 4/6/2016
Flex Pharma (FLKS) Collaborator Penn State University Presents Positive Human Muscle Cramp Data 4/6/2016
Molecular Templates Inc. To Present Clinical And Preclinical Data For MT-3724 And Next Generation Engineered Toxin Bodies (ETBS) At The 2016 AACR Annual Meeting 4/6/2016
Oasmia Reports Positive Clinical Study Results For Proprietary XR17 Nanotechnology 4/5/2016
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) To Present At Needham Healthcare Conference 4/5/2016
Rich Pharma Retains Contract Research Organization, CMIC, To Manage Upcoming Phase 1/2 Clinical Trial For Its Acute Myelocytic Leukemia (AML) And Myelodysplastic Syndrome (MDS) Drug In Thailand 4/4/2016
AbbVie (ABBV) Receives CHMP Positive Opinion For HUMIRA (adalimumab) For The Treatment Of Pediatric Patients, From Six Years Of Age, With Moderately To Severely Active Crohn's Disease 4/4/2016
ORYZON Genomics Announces First Subject Dosed In Phase I Healthy Volunteer Study Evaluating Oral Epigenetic Drug ORY-2001 For Alzheimer's Disease 4/4/2016
Capricor Therapeutics, Inc. Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial 4/4/2016
Stealth Biotherapeutics Announces Presentation Of Elamipretide Data At American College of Cardiology 4/4/2016
Curis (CRIS) Announces Publication Of CUDC-907 Phase I Clinical Trial Data In Lancet Oncology 4/4/2016
ContraVir Invited To Present CMX157 Data At The Oligonucleotide Therapeutics & Delivery Conference 4/4/2016
Navidea (NAVB) Updates Clinical Development Plan For Diagnostic Use Of Lymphoseek IV In Rheumatoid Arthritis 4/4/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry 4/4/2016
Senhwa Biosciences Release: FDA Approves Clinical Trial Application (CTA) For Phase I/II Clinical Trial Of CX-5461 In Solid Tumors And Breast Cancers 4/1/2016
Asterias Biotherapeutics Announces Record Date For Distribution Of Warrants To Holders Of Asterias Series A Common Stock 4/1/2016
Versartis, Inc. (VSAR) Presents Confirmatory 18-Month Adherence Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ENDO Annual Meeting 4/1/2016
Tetra Discovery Partners Advances Alzheimer's Treatment Candidate BPN14770 To Phase I Multiple Ascending Dose Trial 4/1/2016
aTyr Pharma Announces Encouraging Phase 1b/2 Results For Resolaris In Its First Rare Myopathy Trial 3/31/2016
aTyr Pharma Announces Fourth Quarter 2015 Operating Results 3/31/2016
Verastem (VSTM) Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology 3/31/2016
Verastem (VSTM) Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology 3/31/2016
Opthea Completes Patient Enrolment For OPT-302 Phase 1 Dose Escalation Trial In Patients With Wet AMD 3/31/2016
Immunocore's IMCgp100 Starts Phase I Trial For The Treatment Of Uveal Melanoma 3/30/2016
Assembly Biosciences To Present Data On New Series Of HBV Core Protein Allosteric Modifiers At The International Liver Congress™ 2016 3/30/2016
Janssen To Unveil New Hepatitis B And C Data At The International Liver Congress 2016 Of The European Association For The Study Of The Liver (EASL) 3/30/2016
Rich Pharma Further Extends CRO Agreement With Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial For Its Acute Myelocytic Leukemia (AML) And Myelodysplastic Syndrome (MDS) Drug In The United States 3/30/2016
Ironwood (IRWD) To Present Clinical And Preclinical Data On sGC Stimulators At Upcoming Scientific Conferences 3/30/2016
FDA Grants Orphan Drug Designation To Adaptimmune (ADAP)’s T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma 3/30/2016
Oasmia Announces Enrollment Of First Patient In Clinical Study With Docecal, A Novel Formulation Of Docetaxel 3/30/2016
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Provides Fourth Quarter And Year-End 2015 Financial Results 3/29/2016
Geneticure Will Present Promising Data On Improving Treatment For Hypertension At The American Society For Pharmacology And Experimental Therapeutics Annual Meeting 3/29/2016
Tesaro (TSRO) Announces Enrollment Of First Patient In Phase 1 Clinical Trial Of TSR-042 3/29/2016
OXIS International, Inc. (OXIS) Continues Push For Zika Cure, Following New Confirmed Case In South Korea 3/28/2016
DelMar Pharma Announces Abstract Presentations For The AACR Annual Meeting In April 2016 3/24/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015 3/24/2016
Rock Creek Pharma Announces 2015 Annual Results And Provides Commentary And Review 3/23/2016
Asterias Biotherapeutics To Report Fourth Quarter And Full Year 2015 Results On March 29, 2016 3/23/2016
Verastem (VSTM) Announces Oral Presentation Of Data Supporting The Preferential Targeting Of Ovarian Cancer Stem Cells At The Society Of Gynecologic Oncology’s 2016 Annual Meeting On Women’s Cancer 3/23/2016
Ambrx, Inc. And Zhejiang Medicine Co. Ltd Initiated ARX788 First-In-Human Phase I Clinical Trial In Cancer Patients 3/22/2016
Janssen Research & Development Announces The Initiation Of Two Studies Evaluating Daratumumab (DARZALEX) And Atezolizumab In Multiple Myeloma And Solid Tumor 3/22/2016
Mirna To Host Conference Call And Webcast Of Fourth Quarter And Full Year 2015 Financial Results On March 29, 2016 3/22/2016
Bispecific Immunotherapy, The Basis For OXIS International, Inc. (OXIS)' Cancer Drug, Lauded As Promising Alternative To CAR-T Therapy 3/22/2016
Neuropore Therapies Announces Successful Completion Of Phase I With Its Lead Compound NPT200-11 3/22/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
Asana Biosciences To Provide Updates On ASN002, A Novel SYK/JAK Inhibitor, And ASN003, A Novel BRAF/PI3K Kinase Inhibitor, At The 14th International Congress On Targeted Anticancer Therapies 3/21/2016
MabVax Therapeutics, Inc. Initiates Phase I Trial Of Humab-5B1 For Treatment Of Pancreatic Cancer 3/21/2016
ContraVir Initiates Phase 1/2a Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection 3/21/2016
RetroSense Therapeutics Doses First Patient In Phase I/II Clinical Trial For Lead Compound RST-001 3/21/2016
Cerulean Pharma Inc. (CERU) Presents CRLX301 Phase 1 Data At The 14th International Congress On Targeted Anticancer Therapies 3/21/2016
Capricor Therapeutics, Inc. Awarded $3.4 Million Grant From California Institute For Regenerative Medicine 3/18/2016
Catabasis Pharma To Present CAT-1004 Data From Part A Of The MoveDMD Trial At The 2016 Muscular Dystrophy Association Clinical Conference 3/18/2016
SIGA (SIGA) Commences Clinical Study For Intravenous (IV) Formulation Of TPOXX 3/17/2016
Celsion (CLSN) Announces Presentation Of Preclinical Data For GEN-1 IL-12 Immunotherapy In Combination With Avastin And Doxil At The AACR Annual Meeting 2016 3/17/2016
Imperial Innovations Release: Innovations Portfolio Company Topivert Reports Successful Phase I Clinical Study For The Treatment Of Ulcerative Colitis 3/17/2016
Bristol-Myers Squibb (BMY) To Present New Overall Survival Data For Opdivo (nivolumab) As Monotherapy And In Combination With Yervo (ipilimumab) At The AACR 2016 Annual Meeting 3/17/2016
TopiVert Reports Successful Phase I Study With TOP1288 For The Treatment Of Ulcerative Colitis 3/17/2016
Isofol Medical AB Share Issue Oversubscribed, Securing Over SEK 39 Million To Strengthen The Ongoing Phase II Clinical Development Program Of Modufolin 3/17/2016
ARMO BioSciences To Present New Clinical Trial Results For AM0010 At Upcoming Medical Conferences 3/16/2016
Halozyme (HALO) Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE And Gemcitabine 3/16/2016
zuChem Announces Award Of Additional NIH Funding To Support L-fucose Synthesis Program 3/16/2016
Regulus (RGLS) To Present New RG-101 Data At The International Liver Congress 2016 (ILC 2016) 3/16/2016
Opko Health (OPK) Announces Dosing Of First Subject In Phase I Clinical Study Of A Long-Acting Oxyntomodulin For The Treatment Of Obesity And Type II Diabetes 3/16/2016
Adocia And Eli Lilly (LLY) Announce Positive Topline Results From A Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes 3/15/2016
LipoMedics, Inc. Obtained A Phase I SBIR Grant By NIH 3/15/2016
NeuralStem Inc. Reports Fourth Quarter And Year End 2015 Fiscal Results And Business Update 3/15/2016
DelMar Pharma Release: FDA Grants Second Orphan Designation For VAL-083 3/15/2016
uniQure (QURE) Announces Dosing Of First Patient In High-Dose Cohort In Phase I/II Hemophilia B Clinical Trial 3/14/2016
Alnylam (ALNY) Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase I Study 3/14/2016
Intec Pharma Ltd. Completed A Phase I Clinical Trial With Its Third Pipeline Product 3/11/2016
Pfenex (PFNX) Reports Fourth Quarter And Full Year 2015 Results And Provides Business Update 3/11/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Year End Results 3/11/2016
CytRx (CYTR) Reports 2015 Financial Results 3/11/2016
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-402 In CD-19 Positive B-cell Non-Hodgkin Lymphomas 3/11/2016
Report Shows High Doses of Experimental Drug Caused Brain Damage in Bial's Botched Trial in France 3/10/2016
AnaptysBio Announces First-In-Human Dosing Of Anti-IL-33 Antibody 3/10/2016
Pulmatrix Reports 2015 Financial Results; Provides 2016 Outlook On Pulmonary Disease Pipeline 3/10/2016
PsiOxus Initiates Combination Of Paclitaxel With Oncolytic Virus Enadenotucirev In Ovarian Cancer Study 3/10/2016
Ignyta (RXDX) Announces Selection Of Recommended Phase 2 Dose And Initiation Of Phase 1b Basket Trial Of RXDX-105 3/10/2016
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA In Cholangiocarcinoma Cancer 3/10/2016
Umecrine Cognition Raises New Funds To Support Clinical Development Of Novel Drug Candidate GR3027 For Hepatic Encephalopathy - Phase I Clinical Trial Initiated 3/10/2016
Umecrine Cognition Raises New Funds To Support Clinical Development Of Novel Drug Candidate GR3027 For Hepatic Encephalopathy -- Phase I Clinical Trial Initiated 3/10/2016
Alnylam (ALNY) Initiates Phase I/II Clinical Trial For ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 3/9/2016
Theravance Biopharma (TBPH) Announces Positive Results Including Biomarker Data From Phase 1 Study Of TD-0714, An Inhibitor Of Neprilysin (NEP) 3/9/2016
Senhwa Biosciences Enters Into Clinical Trial Agreement With CCTG For Phase I/II Study In Triple Negative Breast Cancer 3/9/2016
GenVec (GNVC) Reports Fourth Quarter And 2015 Year-End Financial Results 3/9/2016
XBiotech Enrolls Final Patient In Phase I Portion Of Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 3/9/2016
Epizyme (EPZM) Unveils Corporate Strategy To Guide Efforts Over Next Five Years 3/9/2016
Epizyme (EPZM) Announces 2015 Financial Results And Financial Guidance 3/9/2016
Trevena (TRVN) Reports Full Year 2015 Financial Results 3/9/2016
BTG plc (BTG.L) Release: New Data From Largest Prospective Study On CroFab For Treatment Of Copperhead Snake Envenomation 3/9/2016
Oncotelic Release: Results Of A Phase I/II Trial Of Ot-101 In Advanced Melanoma Patients 3/9/2016
OWC Pharmaceutical Research Corp. Completes Formulation of Cannabinoid-Infused Topical Cream 3/9/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs 3/8/2016
ImmunoMet Therapeutics Raises $5.2 Million In A Series A Financing 3/8/2016
TopiVert To Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 For The Treatment Of Ulcerative Colitis At The Forthcoming 11th Congress Of ECCO In Amsterdam 3/7/2016
VBI Vaccines Presents New Data Supporting Its Glioblastoma Immunotherapy Program At The Keystone Symposia Cancer Vaccines Conference 3/7/2016
Parkinson's Disease: Prexton Therapeutics Starts Phase 1 Clinical Trial 3/7/2016
Akinion Halts Further Development of AKN-028 Due to Safety Concerns 3/4/2016